CommonWell welcomes two new members

The CommonWell Health Alliance, the health IT vendor-led interoperability coalition, has expanded again.

CVS Caremark and MEDHOST have both joined the alliance as contributing members. CVS Caremark is the largest integrated pharmacy healthcare provider in the U.S. MEDHOST provides a portfolio of enterprise, departmental and community engagement solutions and services to more than 1,000 healthcare facilities nationwide.

"The missions of CommonWell and MEDHOST are closely aligned, specifically that we both are focused on reducing healthcare costs while improving quality of care. We believe that an interoperable healthcare system is good for all stakeholders and ultimately benefits patients, and the care they receive, the most," said Craig Herrod, president of MEDHOST.

"We look forward to making 2014 a year of breaking down health data silos that prevent providers from delivering the highest-quality patient care," said Jeremy Delinsky, chairman of the board for the CommonWell Health Alliance and chief technology officer of athenahealth.

CVS Caremark and MEDHOST join the alliance’s founding members: Allscripts, athenahealth, Cerner, CPSI, Greenway, McKesson and Sunquest and service provider RelayHealth.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.